StockData
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. (SANA) stock

SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.88+0.00 (0.00%)

Close on Nov 17, 2026Market cap $562.80MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$562.80M
P/E ratio
–
Price to sales
–
Price to book
3.64
Dividend yield
–
Free cash flow yield
-24.00%

Fundamentals

Net income
-$211.82M
EPS, diluted
-$0.76
Free cash flow
-$135.06M
Book value per share
$0.52
Diluted shares
296M

Trading

Next earnings
Mar 2, 2027 (estimated, after the close)
Previous close
$1.88
Open
$1.88
Day's range
$1.84 – $1.92
Volume
2,632,566
Average volume (20 days)
2,709,735
Index membership
Russell 2000 (since Jun 2021), Russell 3000 (since May 2021)
52-week range
$1.86 – $5.49
RSI (14 days)
29.8
Volatility (1 year)
76.1%
Relative volume
1.43×

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodSANAS&P 500DifferenceSANA per yearS&P 500 per year
1 month-17.2%-4.0%−13.1 pts
3 months-48.9%-5.0%−43.9 pts
Year to date-53.8%+8.2%−62.1 pts
1 year-48.4%+11.2%−59.6 pts
3 years-55.2%+68.5%−123.7 pts-23.5%+19.0%
5 years-91.4%+67.3%−158.7 pts-38.8%+10.8%

Eight years at a glance

Fiscal years 2018 to 2025 and trailing twelve months, USD

Operating income

-$218.75M

Net income

-$211.82M

EPS, diluted

-$0.76

Free cash flow

-$135.06M
Reported periodTrailing twelve months

Press releases

Releases Sana Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Sana Biotechnology

Biological Products, (No Diagnostic Substances)

This biotechnology company develops ex vivo and in vivo cell engineering platforms to create therapies for severe medical conditions. Its research focuses on treatments for type 1 diabetes, B-cell malignancies, and autoimmune disorders. The firm's primary product candidates include SC451, an engineered stem cell-derived pancreatic islet cell therapy designed to restore normal glucose levels without immunosuppression, and SG293, an in vivo CAR T therapy delivered via fusosomes to deplete disease-causing B cells. These therapeutic candidates target patients diagnosed with insulin-dependent diabetes, hematologic cancers, and B-cell-driven autoimmune diseases.

Company profile, executives and history

Sana Biotechnology stock: common questions

What is Sana Biotechnology's stock price?

SANA closed at $1.88 on Nov 17, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $1.86 and $5.49.

What is Sana Biotechnology's market cap?

Sana Biotechnology was worth $562.80M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is SANA's P/E ratio?

Sana Biotechnology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.76), so it has no meaningful P/E ratio.

Does Sana Biotechnology pay a dividend?

No. Sana Biotechnology has not paid a cash dividend over the last twelve months.

When does Sana Biotechnology report earnings next?

Sana Biotechnology is expected to report Q4 FY2026 results on Mar 2, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has SANA stock performed over the past year?

Including dividends, SANA returned -48.4% over the past year, against +11.2% for the S&P 500.

How many SANA shares are sold short?

41M shares were sold short at the latest FINRA report, 17.63% of the float, or 15.8 days of average trading volume.

Who are Sana Biotechnology's competitors?

Companies most similar to Sana Biotechnology by business, industry and size include IPSC, ALLO, SABS, TCRX, CRBU.

See a number that looks wrong?